ArticleAnnals of surgical oncology2026
Surgical Optimization in Preoperatively Low-risk cN1a PTC: A Predictive Model for High-Volume Central Lymph Node Metastasis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: It Is Time to Distinguish Pseudo-Skip from Classical Lymph Node Skip Metastasis in ESCC.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate preoperative identification of high-volume central lymph node metastasis (hv-CLNM; defined as more than 5 central lymph node metastases) is critical for guiding surgical decisions-lobectomy or total thyroidectomy-in patients with papillary thyroid carcinoma (PTC) clinically diagnosed with central neck lymph node metastasis (cN1a). Total thyroidectomy is generally preferred for patients with hv-CLNM. In contrast, lobectomy may be sufficient for patients with low-volume metastasis (5 or fewer lymph node metastases). This study aimed to identify predictors of hv-CLNM in preoperatively low-risk cN1a and to develop a predictive model to estimate the risk of hv-CLNM, thereby optimizing surgical decision-making.
methodsA total of 707 patients with pathologically confirmed PTC and classified as preoperatively low-risk cN1a were retrospectively enrolled. Clinical and ultrasound features were collected. Variables were selected using least absolute shrinkage and selection operator regression, followed by multivariate logistic regression to construct a predictive model. Internal validation was performed. Recurrence-free survival was compared between lobectomy and total thyroidectomy groups using propensity score matching.
resultsHv-CLNM occurred in 13.4% (96/707) of patients. Independent predictors of hv-CLNM included age, sex, tumor size, tumor location, and lymph node calcification. The nomogram demonstrated good discrimination (area under the plasma concentration-time curve = 0.75) and calibration. After adjustment, recurrence-free survival did not significantly differ between surgical groups.
conclusionsThis nomogram, based on readily available clinical and ultrasound features, effectively predicts the risk of hv-CLNM in preoperatively low-risk cN1a PTC. This tool may facilitate individualized surgical planning. Lobectomy appears to be a safe and appropriate option for most patients in this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.